Camilla Evangelisti

List of Publications by Citations

79 papers	6,833 citations	37 h-index	82 g-index
82 ext. papers	7,507 ext. citations	6.3 avg, IF	5.18 L-index

#	Paper	IF	Citations
79	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2007**, 1773, 1263-84	4.9	1532
78	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget*, **2011**, 2, 135-64	3.3	456
77	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. *Aging*, **2011**, 3, 192-222	5.6	437
76	Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. *Leukemia*, **2006**, 20, 911-28	10.7	269
75	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget*, **2012**, 3, 1068-111	3.3	250
74	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget*, **2012**, 3, 954-87	3.3	214
73	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. *Oncotarget*, **2010**, 1, 89-103	3.3	200
72	Current treatment strategies for inhibiting mTOR in cancer. *Trends in Pharmacological Sciences*, **2015**, 36, 124-35	13.2	195
71	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. *Leukemia*, **2011**, 25, 1080-94	10.7	192
70	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. *Leukemia*, **2011**, 25, 1064-79	10.7	156
69	Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. *Leukemia*, **2007**, 21, 427-38	10.7	151
68	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. *Cancer Research*, **2010**, 70, 8097-107	10.1	136
67	The emerging multiple roles of nuclear Akt. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2012**, 1823, 2168-78	4.9	134
66	Intranuclear 3Sphosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. *Cellular Signalling*, **2006**, 18, 1101-7	4.9	112
65	Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. *Current Medicinal Chemistry*, **2007**, 14, 2009-23	4.3	108
64	Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. *Current Medicinal Chemistry*, **2011**, 18, 2715-26	4.3	100
63	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. *Oncotarget*, **2012**, 3, 371-94	3.3	98

62	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2010**, 1803, 991-1002	4.9	97
61	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. *Leukemia*, **2008**, 22, 147-60	10.7	95
60	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. *Expert Opinion on Investigational Drugs*, **2009**, 18, 1333-49	5.9	94
59	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 449-463	4.9	81
58	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. *Leukemia*, **2011**, 25, 781-91	10.7	79
57	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. *Cancer Research*, **2008**, 68, 9394-403	10.1	76
56	The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. *Leukemia*, **2007**, 21, 886-96	10.7	75
55	Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. *Leukemia*, **2014**, 28, 543-53	10.7	65
54	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. *Leukemia*, **2012**, 26, 2336-42	10.7	63
53	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. *Advances in Enzyme Regulation*, **2007**, 47, 64-103		63
52	Nuclear protein kinase C. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2006**, 1761, 542-51	5	60
51	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. *Leukemia*, **2008**, 22, 2080-90	10.7	59
50	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2015**, 1853, 14-26	4.9	58
49	Therapeutic targeting of CK2 in acute and chronic leukemias. *Leukemia*, **2018**, 32, 1-10	10.7	53
48	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. *Oncotarget*, **2012**, 3, 811-23	3.3	53
47	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2011**, 226, 822-31	7	52
46	Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. *FASEB Journal*, **2007**, 21, 3297-307	0.9	40
45	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. *British Journal of Haematology*, **2005**, 130, 716-25	4.5	40

44	Advances in targeting signal transduction pathways. *Oncotarget*, **2012**, 3, 1505-21	3.3	39
43	Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. *British Journal of Clinical Pharmacology*, **2016**, 82, 1229-1244	3.8	37
42	Targeting the cancer initiating cell: the ultimate target for cancer therapy. *Current Pharmaceutical Design*, **2012**, 18, 1784-95	3.3	36
41	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 729-42	6.4	34
40	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. *Journal of Hematology and Oncology*, **2016**, 9, 114	22.4	33
39	The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. *Cancers*, **2010**, 2, 1576-96	6.6	32
38	Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. *Advances in Biological Regulation*, **2014**, 56, 6-21	6.2	31
37	Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. *Leukemia*, **2010** , 24, 687-98	10.7	31
36	Nuclear inositol lipid metabolism: more than just second messenger generation?. *Journal of Cellular Biochemistry*, **2005**, 96, 285-92	4.7	30
35	Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. *Oncotarget*, **2014**, 5, 7886-901	3.3	30
34	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-B. *Oncotarget*, **2016**, 7, 1323-40	3.3	30
33	Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. *Journal of Cellular Physiology*, **2006**, 209, 370-8	7	29
32	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. *Histology and Histopathology*, **2010**, 25, 669-80	1.4	29
31	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. *Oncotarget*, **2015**, 6, 10399-414	3.3	29
30	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. *Cell Cycle*, **2014**, 13, 2237-47	4.7	28
29	Nuclear phosphoinositides and their roles in cell biology and disease. *Critical Reviews in Biochemistry and Molecular Biology*, **2011**, 46, 436-57	8.7	28
28	Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. *Leukemia*, **2016**, 30, 2142-2151	10.7	26
27	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	24

26	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. *Oncotarget*, **2015**, 6, 7424-37	3.3	24
25	Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. *Cell Cycle*, **2010**, 9, 384-8	4.7	24
24	TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest. *Cellular Signalling*, **2009**, 21, 801-9	4.9	24
23	Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2020**, 235, 5413-5428	7	23
22	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2018**, 233, 1796-1811	7	22
21	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. *Advances in Enzyme Regulation*, **2008**, 48, 113-35		20
20	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). *International Journal of Oncology*, **2014**, 45, 909-18	4.4	19
19	DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. *Cellular Signalling*, **2012**, 24, 1573-82	4.9	19
18	The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	18
17	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. *Advances in Biological Regulation*, **2012**, 52, 214-27	6.2	18
16	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. *Cancers*, **2020**, 12,	6.6	17
15	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	17
14	Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. *Nucleus*, **2018**, 9, 292-304	3.9	15
13	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. *Advances in Biological Regulation*, **2013**, 53, 146-55	6.2	14
12	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. *Expert Opinion on Therapeutic Targets*, **2013**, 17, 921-36	6.4	11
11	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2019**, 1866, 1322-1337	4.9	10
10	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. *Oncotarget*, **2017**, 8, 23213-23227	3.3	10
9	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. *Cells*, **2020**, 9,	7.9	7

8	GSK-3□a key regulator of breast cancer drug resistance. *Cell Cycle*, **2014**, 13, 697-8	4.7	7
7	GSK-3: a multifaceted player in acute leukemias. *Leukemia*, **2021**, 35, 1829-1842	10.7	4
6	The wide and growing range of lamin B-related diseases: from laminopathies to cancer.. *Cellular and Molecular Life Sciences*, **2022**, 79, 126	10.3	3
5	The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). *Current Signal Transduction Therapy*, **2007**, 2, 246-256	0.8	2
4	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. *Cancers*, **2020**, 12,	6.6	2
3	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. *Advances in Biological Regulation*, **2019**, 74, 100649	6.2	1
2	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways **2013**, 331-372		1
1	The PI3K/Akt/mTOR Pathway **2016**, 128-135		1